Prostate cancer and bone metastases: Medical treatment
Prostate cancer and bone metastases: Medical treatment
复制标题
DOI：
10.1097/01.blo.0000093840.72468.e1
复制
发表时间：
2003-10-01
影响因子：
4.2
通讯作者：
Tord, FM
中科院分区：
文献类型：
--
作者：
Clark, PE;Tord, FM
前列腺癌是美国男性最常见的恶性肿瘤。由于前列腺癌的长期自然病史，晚期前列腺癌相关的骨骼发病率的管理成为一个主要的公共卫生问题。晚期前列腺癌的治疗标准是雄激素剥夺疗法。这可能会加速骨质疏松症的发展，并进一步加剧发生与骨骼相关的不良事件的风险。最近，在雄激素剥夺治疗无效的男性中使用双膦酸类药物，随着时间的推移，可以减少骨骼相关事件的发生率。问题仍然是，双膦酸盐是否应该广泛应用于疾病的早期阶段，还是应该为患有骨相关疾病的风险较高的男性量身定做。目前正在进行工作，以改进晚期前列腺癌患者骨转移的其他医疗方法，包括使用放射性药物和联合化疗。
Prostate cancer is the most common malignancy in men in the United States. With the long natural history of the disease, management of skeletal morbidity related to advanced prostate cancer becomes a major public health issue. The standard of care in advanced prostate cancer is androgen deprivation therapy. This may accelerate the development of osteoporosis and further exacerbate the risks of having adverse skeletal-related events develop. Rescently the use of bisphosphonates in men who have not responded to androgen deprivation therapy has been shown to reduce the incidence of skeletal-related events with time. Questions remain as to whether bisphosphonates should be broadly applied to earlier stages of the disease or tailored to men at higher risk of having bone-related morbidity Work is ongoing to improve other approaches to the medical treatment of bone metastases in patients with advanced prostate cancer including the use of radiopharmaceuticals and combined chemotherapy.